Story

NHTSA Reviews Petition to Investigate Air Bags in Over 800,000 Honda Odyssey Minivans

ENTHMSVIIDZHZH-TWJAKOHI
Jul 14, 20261 min read
NHTSA Reviews Petition to Investigate Air Bags in Over 800,000 Honda Odyssey Minivans

Summary

U.S. auto safety regulators are reviewing a request to open an investigation into 806,963 Honda Odyssey minivans from model years 2011-2017. The petition cites concerns over air bags deploying inadvertently while the vehicle is in motion.

Text size
Background

The U.S. National Highway Traffic Safety Administration (NHTSA) has received a petition to open a safety probe into more than 800,000 Honda Odyssey minivans. The request, reported on Tuesday, centers on concerns that the vehicles' air bags could deploy inadvertently while in motion.

Scope of the Potential Probe

The petition specifically targets 806,963 Honda Odyssey models from the 2011 to 2017 model years. According to the NHTSA filing, the core issue cited is the potential for unintended air bag deployment, a significant safety concern for drivers and passengers.

At this stage, the agency has only received the request and has not yet launched a formal investigation. Regulators will first review the petition to determine if a full defect probe is warranted.

Sample IUX Markets – In-articleAd

Market Context

A formal investigation by the NHTSA is the first step in a process that could potentially lead to a vehicle recall, which can carry significant financial and reputational costs for an automaker. The Odyssey is one of Honda's popular family vehicles in the U.S. market.

According to a Reuters report, Honda did not immediately provide a comment on the matter. Investors will be watching to see if the NHTSA grants the petition and proceeds with a formal engineering analysis.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST